In a phase I trial of avapritinib (formerly BLU-285), which targets D816V mutant 
KIT, for the treatment of advanced systemic mastocytosis, patients experienced 
rapid and durable disease control. The overall response rate was 72%, and 56% of 
patients experienced a complete or partial response. No patients discontinued 
treatment due to adverse events, most of which were mild to moderate in nature.